1. Home
  2. ANTX vs DERM Comparison

ANTX vs DERM Comparison

Compare ANTX & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AN2 Therapeutics Inc.

ANTX

AN2 Therapeutics Inc.

HOLD

Current Price

$4.75

Market Cap

170.6M

Sector

Health Care

ML Signal

HOLD

DERM

Journey Medical Corporation

HOLD

Current Price

$5.02

Market Cap

135.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANTX
DERM
Founded
2017
2014
Country
United States
United States
Employees
21
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
170.6M
135.3M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
ANTX
DERM
Price
$4.75
$5.02
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$2.00
$12.67
AVG Volume (30 Days)
334.8K
187.9K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
32.56
34.72
EPS
N/A
N/A
Revenue
N/A
$61,858,000.00
Revenue This Year
N/A
$39.72
Revenue Next Year
N/A
$63.24
P/E Ratio
N/A
N/A
Revenue Growth
N/A
10.20
52 Week Low
$1.00
$4.31
52 Week High
$6.91
$9.56

Technical Indicators

Market Signals
Indicator
ANTX
DERM
Relative Strength Index (RSI) 70.62 38.37
Support Level $1.06 $4.31
Resistance Level $6.91 $5.60
Average True Range (ATR) 0.36 0.26
MACD 0.13 0.10
Stochastic Oscillator 81.23 15.71

Price Performance

Historical Comparison
ANTX
DERM

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

About DERM Journey Medical Corporation

Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.

Share on Social Networks: